IL6 and hepatocellular carcinoma: reported that CAF-derived IL-6 induces PD-L1+ neutrophils via the JAK-STAT3 pathway, which impairs T cell function through PD-1/PD-L1 signaling, and then creates optimal conditions for human hepatocellular carcinoma progression (69) (Figure 1).